Mike Brown, director and containment specialist at ONFAB - part of Envair Technology - explains the growing use of HPAPIs and the demand for flexible containment that this has created.
The use of highly potent active pharmaceutical ingredients (HPAPIs) in drug development has increased markedly across Europe and the US in the last couple of decades – particularly as oncology research has advanced and targeted therapies have become more commonplace.